Cardiff Oncology, Inc. CRDF 深 滬
等待開盤 03-26 09:30:00 美东时间
1.73
0.000
0.00%
華盛通- 最 高1.80
- 今 開1.76
- 成交量 43.61万股
- 最 低 1.71
- 昨 收 1.73
- 總市值 1.18亿
- 52周最高 4.555
- 市盈率 靜 --
- 換手率 0.64%
- 52周最低 1.48
- 委 比 -35.44%
- 總股本 6836.50万
- 歷史最高 977.76
- 量 比 0.83
- 振 幅 5.20%
- 歷史最低 0.701
- 每 手 1
- 風險率 0.68%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cardiff Oncology To Host Key Opinion Leader Webinar To Discuss Emergent Treatment Landscape In First-Line RAS-Mutated Metastatic Colorectal Cancer On March 25
Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that the Company will host a key opinion
03-20 19:03
美股大行评级 | 大摩将应用材料目标价升至432美元；潜在涨幅200.0%！维尔生物科技获巴克莱升目标价至30美元，维持"超配"评级
今日重点评级关注：巴克莱：维持Vir Biotechnology"超配"评级，目标价从26美元升至30美元；巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从10美元升至11美元
02-26 09:30
Piper Sandler Maintains Overweight on Cardiff Oncology, Lowers Price Target to $6
Piper Sandler analyst Edward Tenthoff maintains Cardiff Oncology (NASDAQ:CRDF) with a Overweight and lowers the price target from $10 to $6.
02-25 22:40
Cardiff Oncology Q4 EPS $(0.11) Beats $(0.20) Estimate, Sales $243.000K Beat $105.556K Estimate
Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.20) by 44.72 percent. This is a 47.62 percent increase over losses of $(0.21) per share from
02-25 05:59
美股大行评级 | 希捷科技、德州仪器、HCA控股、通用汽车、波音、UPS等或多家机构上调目标价；布朗保险、康沃系统、Qorvo、联合健康等遭多家机构下调目标价
今日重点评级关注：Piper Sandler：维持Praxis Precision Medicine"超配"评级，目标价从450美元升至1200美元；Tigress Financial：维持Main International ETF"买入"评级，目标价从52美元升至66美元
01-29 11:06
Cardiff Oncology Names Mani Mohindru Interim CEO
Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support
01-28 00:17
Cardiff Oncology Announces Update From CRDF-004, Phase 2 Clinical Trial Evaluating Onvansertib In Combination With SoC Regimens In Patients With 1L RAS- mCRC
- Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in patients with
01-27 20:07
Cardiff Oncology Reports Early Onvansertib Monotherapy Activity In Phase 1 CMML Trial Ahead Of ASH 2025 Poster Presentation
Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that clinical data from an
2025-12-09 05:06
Cardiff Oncology Q3 EPS $(0.17) Beats $(0.20) Estimate, Sales $120.000K Beat $112.500K Estimate
Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.20) by 15.42 percent. This is a 32 percent increase over losses of $(0.25) per share from the
2025-11-07 05:37
Cardiff Oncology to Participate in Three Upcoming Investor Conferences
Cardiff Oncology宣布其管理层将参加2025年9月的三场投资者会议，包括Wells Fargo、Morgan Stanley和H.C. Wainwright的年度医疗与投资大会。公司通过PLK1抑制剂开发抗癌疗法，重点治疗结直肠癌、胰腺癌等。会议详情见公司网站。
2025-08-28 20:05
